A multinational drugmaker is paying 45 states including South Dakota $105 million to settle complaints that the company unlawfully marketed three drugs.
South Dakota Attorney General Marty Jackley says South Dakota's share of the settlement is nearly $1.2 million.
The settlement resolves allegations that London-based Glaxo illegally marketed Advair, Paxil and Wellbutrin for purposes that had not been approved by the Food and Drug Administration. Once the FDA approves a drug as safe and effective, a manufacturer cannot market or promote that drug for an unapproved use, a practice called off-label marketing.
The asthma treatment Advair is Glaxo's best-selling product. Paxil and Wellbutrin are antidepressant drugs.
Most Popular Today
- 1.Recalls, General
Ford Recalls Nearly 423K Vehicles For Power Steering Problem
Software Glitch Can Cause iPhones To Crash
- 3.Your Money Matters
Changing Face Of 41st Street
- 4.Your Money Matters
Downtown Sioux Falls Store Featured By Google
- 5.Gas & Energy
BNSF, Power Plant Owner Settle Long-Running Rate Dispute
- 6.Health Care
Med-Star Settling Into New Location
- 7.Education Funding
Rutland School District Residents To Vote Again On Opt Out
- 8.Your Money Matters
Business Succeeding Online
City/State Development Partnership To Be Announced
- 10.Gas & Energy
Federal Commission Asked To Review Proposed Uranium Mine